The ophthalmology drugs market covers
drugs that are used in the treatment of eye-related
diseases such as refractive errors, cataracts, glaucoma, conjunctivitis,
retinal diseases, and macular degeneration. Some of the major ophthalmic drugs
include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax. The market
numbers in this briefing cover pharmaceutical (drug) treatments and do not
cover biologic treatments for these conditions which are included in a separate
briefing.
Read the report at
The ophthalmic
devices market is valued at nearly $31 billion in 2017 due
to prevalence of eye conditions such as age-related degeneration,
diabetic retinopathy and glaucoma.
North America was the largest geographic region, accounting for almost thirty-percent of
the global market.
The ophthalmic
devices market in The Business Research Company’s report
is segmented into antiglaucoma drugs, dry
eye medication, and other
ophthalmological drugs.
Download a sample of the report at
The USA was the
largest country, accounting for near about thirty percent share of the global ophthalmic devices market in 2017. This is due to high per capita healthcare expenditure and increasing
geriatric population in the country. The USA was
followed by Germany and Japan.
The top five competitors in the market
are Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc., Valeant
Pharmaceuticals Intl Inc., and Bayer AG. Novartis AG was the biggest player in
the market 2017. It is a multinational pharmaceutical company that develops,
manufacture and markets healthcare products. The company is headquartered in
Basel, Switzerland.
About The Business Research Company.
The Business Research Company is a
Business Intelligence Company which excels in company, market and consumer
research. It has offices in the UK, the US and India and a network of trained
researchers in 15 countries globally.
Contact Information.
The Business Research Company
Europe: +44
207 1930 708
Asia: +91
8897263534
Americas:
+1 315 623 0293
No comments:
Post a Comment